A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...

A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...

Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.

A larger percentage of GLP-1 users say social media and online research are their most trusted source for microdosing ...

This opens the door to making mistakes—ones that could worsen your side effects, affect how much weight you’ll lose, or even ...

Changes in purchasing patterns after glucagon-like peptide-1 receptor agonist (GLP-1RA) initiation were seen across most nutrient ...

Tirzepatide users on hormone therapy had added improvements in weight, cardiometabolic mar ...

Is Obesity Genetic or Environmental? Get All the Details This article was reviewed by Lynn Marie Morski, MD, JD. Key ...